China Medical System Holdings Ltd. (HK:0867)
:0867
Want to see HK:0867 full AI Analyst Report?
0867 Stock Chart & Stats
HK$14.20
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$14.20
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$10.00 - HK$15.63
Previous CloseN/A
Volume2.83M
Average Volume (3M)6.44M
Market Cap
HK$26.52B
Enterprise ValueHK$20.28B
Total Cash (Recent Filing)HK$5.79B
Total Debt (Recent Filing)HK$690.37M
Price to Earnings (P/E)15.3
Beta0.92
Next Earnings
Aug 13, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend Yield2.26%
Share Statistics
EPS (TTM)0.61
Shares Outstanding2,439,528,600
10 Day Avg. Volume4,711,227
30 Day Avg. Volume6,437,247
Financial Highlights & Ratios
PEG Ratio-2.52
Price to Book (P/B)1.61
Price to Sales (P/S)3.41
P/FCF Ratio114.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.62Price Target Upside31.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.83
Revenue Forecast (FY)HK$9.93B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and steadily growing equity give the company durable financial flexibility to fund launches, absorb setbacks, and pursue licensing or tuck-in deals without stressing liquidity. This conservatism supports stability across cycles and preserves strategic optionality.
High MarginsSustained high gross and healthy net margins reflect structural pricing power from specialty products and efficient commercialization. Margin durability cushions earnings during revenue swings and supports reinvestment in marketing, registration or selective pipeline expansion.
Commercialization/licensing ModelAn asset-light model centered on in-licensing and commercializing branded drugs reduces upfront R&D risk and leverages existing sales infrastructure. This creates diversified revenue streams (sales, milestones, royalties) and scales returns from a repeatable commercialization capability.
Bears Say
Weakening Cash GenerationThe sharp decline in operating and free cash flow in 2025 materially reduces internal funding for new launches, dividends, or M&A. Persistently weaker cash conversion increases reliance on partners or external capital and limits the firm's ability to withstand prolonged profit pressure.
Earnings And ROE DeteriorationA multi-year decline in net income and returns on equity signals meaningful erosion of earnings power. Lower profitability constrains self‑funding for growth, weakens capital allocation optionality, and indicates structural margin or competitive pressures that may persist without product or cost fixes.
Revenue VolatilityMaterial top-line volatility reduces forecasting reliability and suggests dependence on timing of launches or a handful of key products. Persistent revenue swings complicate inventory, marketing spend and strategic planning, making sustained cash flow and margin improvement harder to predict.
China Medical System Holdings News
0867 FAQ
What was China Medical System Holdings Ltd.’s price range in the past 12 months?
China Medical System Holdings Ltd. lowest stock price was HK$10.00 and its highest was HK$15.63 in the past 12 months.
What is China Medical System Holdings Ltd.’s market cap?
China Medical System Holdings Ltd.’s market cap is HK$26.52B.
When is China Medical System Holdings Ltd.’s upcoming earnings report date?
China Medical System Holdings Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 63 days.
How were China Medical System Holdings Ltd.’s earnings last quarter?
China Medical System Holdings Ltd. released its earnings results on Mar 16, 2026. The company reported HK$0.262 earnings per share for the quarter, missing the consensus estimate of HK$0.33 by -HK$0.068.
Is China Medical System Holdings Ltd. overvalued?
According to Wall Street analysts China Medical System Holdings Ltd.’s price is currently Undervalued.
Does China Medical System Holdings Ltd. pay dividends?
China Medical System Holdings Ltd. pays a Semiannually dividend of HK$0.155 which represents an annual dividend yield of 2.26%. See more information on China Medical System Holdings Ltd. dividends here
What is China Medical System Holdings Ltd.’s EPS estimate?
China Medical System Holdings Ltd.’s EPS estimate is 0.46.
How many shares outstanding does China Medical System Holdings Ltd. have?
China Medical System Holdings Ltd. has 2,439,528,600 shares outstanding.
What happened to China Medical System Holdings Ltd.’s price movement after its last earnings report?
China Medical System Holdings Ltd. reported an EPS of HK$0.262 in its last earnings report, missing expectations of HK$0.33. Following the earnings report the stock price went up 2.444%.
Which hedge fund is a major shareholder of China Medical System Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0867
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Medical System Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.75%
12-Months-Change
Fundamentals
Return on Equity
8.60%
Trailing 12-Months
Asset Growth
11.11%
Trailing 12-Months
Company Description
China Medical System Holdings Ltd.
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
0867 Stock 12 Month Forecast
Average Price Target
HK$18.62
▲(31.10% Upside)
Technical Analysis
The United Laboratories International Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---